5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Pulmonary O
Toxicity O
: O
Permanently O
discontinue O
KADCYLA O
in O
patients O
diagnosed O
with O
interstitial O
lung O
disease O
or O
pneumonitis O
. O

( O
2.2 O
, O
5.4 O
) O
* O
Infusion-Related O
Reactions O
, O
Hypersensitivity O
Reactions O
: O
Monitor O
for O
signs O
and O
symptoms O
during O
and O
after O
infusion O
. O

If O
significant O
infusion-related O
reactions O
or O
hypersensitivity O
reactions O
occur O
, O
slow O
or O
interrupt O
the O
infusion O
and O
administer O
appropriate O
medical O
therapies O
. O

Permanently O
discontinue O
KADCYLA O
for O
life O
threatening O
infusion-related O
reaction O
. O

( O
2.1 O
, O
2.2 O
, O
5.5 O
) O
* O
Hemorrhage O
: O
Fatal O
cases O
of O
hemorrhage O
occurred O
in O
clinical O
trials O
among O
patients O
with O
no O
known O
identified O
risk O
factors O
, O
as O
well O
as O
among O
patients O
with O
thrombocytopenia O
and O
those O
receiving O
anti-coagulation O
and O
antiplatelet O
therapy O
. O

Use O
caution O
with O
these O
agents O
and O
consider O
additional O
monitoring O
when O
concomitant O
use O
is O
medically O
necessary O
. O

( O
5.6 O
) O
* O
Thrombocytopenia O
: O
Monitor O
platelet O
counts O
prior O
to O
each O
KADCYLA O
dose O
. O

Institute O
dose O
modifications O
as O
appropriate O
. O

( O
2.2 O
, O
5.7 O
) O
* O
Neurotoxicity O
: O
Monitor O
for O
signs O
or O
symptoms O
. O

Withhold O
dosing O
temporarily O
for O
patients O
experiencing O
Grade O
3 O
or O
4 O
peripheral O
neuropathy O
. O

( O
2.2 O
, O
5.8 O
, O
13.2 O
) O
* O
HER2 O
Testing O
: O
Perform O
using O
FDA-approved O
tests O
by O
laboratories O
with O
demonstrated O
proficiency O
. O

( O
5.9 O
) O
5.1 O
Hepatotoxicity O
Hepatotoxicity B-OSE_Labeled_AE
, O
predominantly O
in O
the O
form O
of O
asymptomatic O
, O
transient O
increases B-OSE_Labeled_AE
in O
the O
concentrations O
of O
serum O
transaminases I-OSE_Labeled_AE
, O
has O
been O
observed O
in O
clinical O
trials O
with O
KADCYLA O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Serious O
hepatobiliary B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
including O
at O
least O
two O
fatal B-NonOSE_AE
cases O
of O
severe O
drug B-OSE_Labeled_AE
- I-OSE_Labeled_AE
induced I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
injury I-OSE_Labeled_AE
and O
associated O
hepatic B-OSE_Labeled_AE
encephalopathy I-OSE_Labeled_AE
, O
have O
been O
reported O
in O
clinical O
trials O
with O
KADCYLA O
. O

Some O
of O
the O
observed O
cases O
may O
have O
been O
confounded O
by O
comorbidities O
and/or O
concomitant O
medications O
with O
known O
hepatotoxic B-NonOSE_AE
potential O
. O

Monitor O
serum O
transaminases O
and O
bilirubin O
prior O
to O
initiation O
of O
KADCYLA O
treatment O
and O
prior O
to O
each O
KADCYLA O
dose O
. O

Patients O
with O
known O
active O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
virus I-Not_AE_Candidate
or O
hepatitis B-Not_AE_Candidate
C I-Not_AE_Candidate
virus I-Not_AE_Candidate
were O
excluded O
from O
Study O
1 O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

Reduce O
the O
dose O
or O
discontinue O
KADCYLA O
as O
appropriate O
in O
cases O
of O
increased B-NonOSE_AE
serum I-NonOSE_AE
transaminases I-NonOSE_AE
and/or O
total O
bilirubin O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

Permanently O
discontinue O
KADCYLA O
treatment O
in O
patients O
with O
serum B-NonOSE_AE
transaminases I-NonOSE_AE
> I-NonOSE_AE
3 I-NonOSE_AE
* I-NonOSE_AE
ULN I-NonOSE_AE
and O
concomitant O
total B-NonOSE_AE
bilirubin I-NonOSE_AE
> I-NonOSE_AE
2 I-NonOSE_AE
* I-NonOSE_AE
ULN I-NonOSE_AE
. O

KADCYLA O
has O
not O
been O
studied O
in O
patients O
with O
serum O
transaminases B-NonOSE_AE
> I-NonOSE_AE
2 I-NonOSE_AE
. I-NonOSE_AE
5 I-NonOSE_AE
* I-NonOSE_AE
ULN I-NonOSE_AE
or O
bilirubin B-NonOSE_AE
> I-NonOSE_AE
1 I-NonOSE_AE
. I-NonOSE_AE
5 I-NonOSE_AE
* I-NonOSE_AE
ULN I-NonOSE_AE
prior O
to O
the O
initiation O
of O
treatment O
. O

In O
clinical O
trials O
of O
KADCYLA O
, O
cases O
of O
nodular B-OSE_Labeled_AE
regenerative I-OSE_Labeled_AE
hyperplasia I-OSE_Labeled_AE
( I-OSE_Labeled_AE
NRH I-OSE_Labeled_AE
) O
of O
the O
liver O
have O
been O
identified O
from O
liver O
biopsies O
( O
3 O
cases O
out O
of O
884 O
treated O
patients O
, O
one O
of O
which O
was O
fatal B-NonOSE_AE
) O
. O

Two O
of O
these O
three O
cases O
of O
NRH B-OSE_Labeled_AE
were O
observed O
in O
the O
randomized O
trial O
( O
Study O
1 O
) O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

NRH B-NonOSE_AE
is O
a O
rare O
liver B-NonOSE_AE
condition I-NonOSE_AE
characterized I-NonOSE_AE
by I-NonOSE_AE
widespread I-NonOSE_AE
benign I-NonOSE_AE
transformation I-NonOSE_AE
of I-NonOSE_AE
hepatic I-NonOSE_AE
parenchyma I-NonOSE_AE
into I-NonOSE_AE
small I-NonOSE_AE
regenerative I-NonOSE_AE
nodules I-NonOSE_AE
; O
NRH B-NonOSE_AE
may O
lead O
to O
non B-NonOSE_AE
- I-NonOSE_AE
cirrhotic I-NonOSE_AE
portal I-NonOSE_AE
hypertension I-NonOSE_AE
. O

The O
diagnosis O
of O
NRH B-NonOSE_AE
can O
be O
confirmed O
only O
by O
histopathology O
. O

NRH B-NonOSE_AE
should O
be O
considered O
in O
all O
patients O
with O
clinical O
symptoms O
of O
portal B-NonOSE_AE
hypertension I-NonOSE_AE
and/or O
cirrhosis B-NonOSE_AE
- I-NonOSE_AE
like I-NonOSE_AE
pattern I-NonOSE_AE
seen O
on O
the O
computed O
tomography O
( O
CT O
) O
scan O
of O
the O
liver O
but O
with O
normal O
transaminases O
and O
no O
other O
manifestations O
of O
cirrhosis B-NonOSE_AE
. O

Upon O
diagnosis O
of O
NRH B-NonOSE_AE
, O
KADCYLA O
treatment O
must O
be O
permanently O
discontinued O
. O

5.2 O
Left O
Ventricular O
Dysfunction O
Patients O
treated O
with O
KADCYLA O
are O
at O
increased O
risk O
of O
developing O
left B-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
. O

A O
decrease B-OSE_Labeled_AE
of I-OSE_Labeled_AE
LVEF I-OSE_Labeled_AE
to I-OSE_Labeled_AE
< I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
% I-OSE_Labeled_AE
has O
been O
observed O
in O
patients O
treated O
with O
KADCYLA O
. O

In O
the O
randomized O
trial O
( O
Study O
1 O
) O
, O
left B-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
occurred O
in O
1.8 O
% O
of O
patients O
in O
the O
KADCYLA-treated O
group O
and O
3.3 O
% O
of O
patients O
in O
the O
lapatinib O
plus O
capecitabine-treated O
group O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Assess O
LVEF O
prior O
to O
initiation O
of O
KADCYLA O
and O
at O
regular O
intervals O
( O
e.g O
. O

every O
three O
months O
) O
during O
treatment O
to O
ensure O
the O
LVEF O
is O
within O
the O
institution O
's O
normal O
limits O
. O

Treatment O
with O
KADCYLA O
has O
not O
been O
studied O
in O
patients O
with O
LVEF B-Not_AE_Candidate
< I-Not_AE_Candidate
5 I-Not_AE_Candidate
0 I-Not_AE_Candidate
% I-Not_AE_Candidate
prior O
to O
initiation O
of O
treatment O
. O

If O
, O
at O
routine O
monitoring O
, O
LVEF B-NonOSE_AE
is O
< O
40 O
% O
, O
or O
is O
40 O
% O
to O
45 O
% O
with O
a O
10 O
% O
or O
greater O
absolute O
decrease I-NonOSE_AE
below O
the O
pretreatment O
value O
, O
withhold O
KADCYLA O
and O
repeat O
LVEF O
assessment O
within O
approximately O
3 O
weeks O
. O

Permanently O
discontinue O
KADCYLA O
if O
the O
LVEF O
has O
not O
improved O
or O
has O
declined O
further O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

Patients O
with O
a O
history O
of O
symptomatic B-Not_AE_Candidate
congestive I-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
( I-Not_AE_Candidate
CHF I-Not_AE_Candidate
) O
, O
serious O
cardiac B-Not_AE_Candidate
arrhythmia I-Not_AE_Candidate
, O
or O
history B-Not_AE_Candidate
of I-Not_AE_Candidate
myocardial I-Not_AE_Candidate
infarction I-Not_AE_Candidate
or O
unstable B-Not_AE_Candidate
angina I-Not_AE_Candidate
within O
6 O
months O
were O
excluded O
from O
Study O
1 O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

5.3 O
Embryo-Fetal O
Toxicity O
KADCYLA O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
. O

There O
are O
no O
adequate O
and O
well-controlled O
studies O
of O
KADCYLA O
in O
pregnant B-Not_AE_Candidate
women O
and O
no O
reproductive O
and O
developmental O
toxicology O
studies O
have O
been O
conducted O
with O
ado-trastuzumab O
emtansine O
. O

Nevertheless O
, O
treatment O
with O
trastuzumab O
, O
the O
antibody O
component O
of O
KADCYLA O
, O
during O
pregnancy B-Not_AE_Candidate
in O
the O
postmarketing O
setting O
has O
resulted O
in O
oligohydramnios B-OSE_Labeled_AE
, O
some O
associated O
with O
fatal B-NonOSE_AE
pulmonary B-OSE_Labeled_AE
hypoplasia I-OSE_Labeled_AE
, O
skeletal B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
and O
neonatal B-OSE_Labeled_AE
death I-OSE_Labeled_AE
. O

DM1 O
, O
the O
cytotoxic B-NonOSE_AE
component O
of O
KADCYLA O
, O
can O
be O
expected O
to O
cause O
embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
fetal I-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
based O
on O
its O
mechanism O
of O
action O
. O

If O
KADCYLA O
is O
used O
during O
pregnancy B-Not_AE_Candidate
, O
or O
if O
the O
patient O
becomes O
pregnant B-NonOSE_AE
while O
receiving O
KADCYLA O
or O
within O
7 O
months O
following O
the O
last O
dose O
of O
KADCYLA O
, O
apprise O
the O
patient O
of O
the O
potential O
hazard B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

Verify O
pregnancy B-NonOSE_AE
status O
prior O
to O
the O
initiation O
of O
KADCYLA O
. O

Advise O
patients O
of O
the O
risks O
of O
embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
fetal I-OSE_Labeled_AE
death I-OSE_Labeled_AE
and O
birth B-OSE_Labeled_AE
defects I-OSE_Labeled_AE
and O
the O
need O
for O
contraception O
during O
and O
after O
treatment O
. O

Advise O
patients O
to O
contact O
their O
healthcare O
provider O
immediately O
if O
they O
suspect O
they O
may O
be O
pregnant B-NonOSE_AE
. O

If O
KADCYLA O
is O
administered O
during O
pregnancy B-Not_AE_Candidate
or O
if O
a O
patient O
becomes O
pregnant B-NonOSE_AE
while O
receiving O
KADCYLA O
or O
within O
7 O
months O
following O
the O
last O
dose O
of O
KADCYLA O
, O
immediately O
report O
exposure O
to O
the O
Genentech O
Adverse O
Event O
Line O
at O
1-888-835-2555 O
. O

Encourage O
women O
who O
may O
be O
exposed O
during O
pregnancy B-NonOSE_AE
or O
within O
7 O
months O
prior O
to O
conception O
, O
to O
enroll O
in O
the O
MotHER O
Pregnancy B-NonOSE_AE
Registry O
by O
contacting O
1-800-690-6720 O
[ O
see O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.4 O
Pulmonary B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Cases O
of O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ILD I-OSE_Labeled_AE
) O
, O
including O
pneumonitis B-OSE_Labeled_AE
, O
some O
leading O
to O
acute B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
distress I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
or O
fatal B-NonOSE_AE
outcome O
have O
been O
reported O
in O
clinical O
trials O
with O
KADCYLA O
. O

Pneumonitis B-OSE_Labeled_AE
at O
an O
incidence O
of O
0.8 O
% O
( O
7 O
out O
of O
884 O
treated O
patients O
) O
has O
been O
reported O
, O
with O
one O
case O
of O
grade O
3 O
pneumonitis B-OSE_Labeled_AE
. O

Signs O
and O
symptoms O
include O
dyspnea B-NonOSE_AE
, O
cough B-NonOSE_AE
, O
fatigue B-NonOSE_AE
, O
and O
pulmonary B-NonOSE_AE
infiltrates I-NonOSE_AE
. O

These O
events O
may O
or O
may O
not O
occur O
as O
sequelae O
of O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
. O

In O
the O
randomized O
trial O
( O
Study O
1 O
) O
, O
the O
overall O
frequency O
of O
pneumonitis B-OSE_Labeled_AE
was O
1.2 O
% O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Permanently O
discontinue O
treatment O
with O
KADCYLA O
in O
patients O
diagnosed O
with O
ILD B-NonOSE_AE
or O
pneumonitis B-NonOSE_AE
. O

Patients O
with O
dyspnea B-Not_AE_Candidate
at I-Not_AE_Candidate
rest I-Not_AE_Candidate
due O
to O
complications O
of O
advanced B-Not_AE_Candidate
malignancy I-Not_AE_Candidate
and O
co-morbidities O
may O
be O
at O
increased O
risk O
of O
pulmonary B-NonOSE_AE
toxicity I-NonOSE_AE
. O

5.5 O
Infusion-Related O
Reactions O
, O
Hypersensitivity O
Reactions O
Treatment O
with O
KADCYLA O
has O
not O
been O
studied O
in O
patients O
who O
had O
trastuzumab O
permanently O
discontinued O
due O
to O
infusion B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
reactions I-NonOSE_AE
( I-NonOSE_AE
IRR I-NonOSE_AE
) O
and/or O
hypersensitivity B-NonOSE_AE
; O
treatment O
with O
KADCYLA O
is O
not O
recommended O
for O
these O
patients O
. O

Infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
characterized O
by O
one O
or O
more O
of O
the O
following O
symptoms O
- O
flushing B-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
wheezing B-OSE_Labeled_AE
, O
bronchospasm B-OSE_Labeled_AE
, O
and O
tachycardia B-OSE_Labeled_AE
have O
been O
reported O
in O
clinical O
trials O
of O
KADCYLA O
. O

In O
the O
randomized O
trial O
( O
Study O
1 O
) O
, O
the O
overall O
frequency O
of O
IRRs B-OSE_Labeled_AE
in O
patients O
treated O
with O
KADCYLA O
was O
1.4 O
% O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

In O
most O
patients O
, O
these O
reactions O
resolved O
over O
the O
course O
of O
several O
hours O
to O
a O
day O
after O
the O
infusion O
was O
terminated O
. O

KADCYLA O
treatment O
should O
be O
interrupted O
in O
patients O
with O
severe O
IRR B-NonOSE_AE
. O

KADCYLA O
treatment O
should O
be O
permanently O
discontinued O
in O
the O
event O
of O
a O
life-threatening O
IRR B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

Patients O
should O
be O
observed O
closely O
for O
IRR B-NonOSE_AE
reactions O
, O
especially O
during O
the O
first O
infusion O
. O

One O
case O
of O
a O
serious O
, O
allergic B-OSE_Labeled_AE
/anaphylactic-like O
reaction I-OSE_Labeled_AE
has O
been O
observed O
in O
clinical O
trials O
of O
single-agent O
KADCYLA O
. O

Medications O
to O
treat O
such O
reactions O
, O
as O
well O
as O
emergency O
equipment O
, O
should O
be O
available O
for O
immediate O
use O
. O

5.6 O
Hemorrhage O
Cases O
of O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
including O
central B-OSE_Labeled_AE
nervous I-OSE_Labeled_AE
system I-OSE_Labeled_AE
, O
respiratory O
, O
and O
gastrointestinal O
hemorrhage I-OSE_Labeled_AE
, O
have O
been O
reported O
in O
clinical O
trials O
with O
Kadcyla O
. O

Some O
of O
these O
bleeding B-OSE_Labeled_AE
events O
resulted O
in O
fatal B-NonOSE_AE
outcomes O
. O

In O
the O
randomized O
trial O
( O
Study O
1 O
) O
, O
the O
overall O
frequency O
of O
hemorrhage B-OSE_Labeled_AE
was O
32.2 O
% O
in O
the O
KADCYLA-treated O
group O
and O
16.4 O
% O
in O
the O
lapatinib O
plus O
capecitabine-treated O
group O
. O

The O
incidence O
of O
> O
= O
Grade O
3 O
hemorrhage B-OSE_Labeled_AE
was O
1.8 O
% O
in O
the O
KADCYLA-treated O
group O
and O
0.8 O
% O
in O
the O
lapatinib O
plus O
capecitabine-treated O
group O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Although O
, O
in O
some O
of O
the O
observed O
cases O
the O
patients O
were O
also O
receiving O
anti-coagulation O
therapy O
, O
antiplatelet O
therapy O
, O
or O
had O
thrombocytopenia B-Not_AE_Candidate
, O
in O
others O
there O
were O
no O
known O
additional O
risk O
factors O
. O

Use O
caution O
with O
these O
agents O
and O
consider O
additional O
monitoring O
when O
concomitant O
use O
is O
medically O
necessary O
. O

5.7 O
Thrombocytopenia O
Thrombocytopenia B-OSE_Labeled_AE
, O
or O
decreased B-OSE_Labeled_AE
platelet I-OSE_Labeled_AE
count I-OSE_Labeled_AE
, O
was O
reported O
in O
clinical O
trials O
of O
KADCYLA O
( O
103 O
of O
884 O
treated O
patients O
with O
> O
= O
Grade O
3 O
; O
283 O
of O
884 O
treated O
patients O
with O
any O
Grade O
) O
. O

The O
majority O
of O
these O
patients O
had O
Grade O
1 O
or O
2 O
events O
( O
< O
LLN O
to O
> O
= O
50,000/mm O
3 O
) O
with O
the O
nadir O
occurring O
by O
day O
8 O
and O
generally O
improving O
to O
Grade O
0 O
or O
1 O
( O
> O
= O
75,000 O
/mm O
3 O
) O
by O
the O
next O
scheduled O
dose O
. O

In O
clinical O
trials O
of O
KADCYLA O
, O
the O
incidence O
and O
severity O
of O
thrombocytopenia B-NonOSE_AE
were O
higher O
in O
Asian O
patients O
. O

In O
the O
randomized O
trial O
( O
Study O
1 O
) O
, O
the O
overall O
frequency O
of O
thrombocytopenia B-OSE_Labeled_AE
was O
31.2 O
% O
in O
the O
KADCYLA-treated O
group O
and O
3.3 O
% O
in O
the O
lapatinib O
plus O
capecitabine-treated O
group O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

The O
incidence O
of O
> O
= O
Grade O
3 O
thrombocytopenia B-OSE_Labeled_AE
was O
14.5 O
% O
in O
the O
KADCYLA-treated O
group O
and O
0.4 O
% O
in O
the O
lapatinib O
plus O
capecitabine-treated O
group O
. O

In O
Asian O
patients O
, O
the O
incidence O
of O
> O
= O
Grade O
3 O
thrombocytopenia B-OSE_Labeled_AE
was O
45.1 O
% O
in O
the O
KADCYLA-treated O
group O
and O
1.3 O
% O
in O
the O
lapatinib O
plus O
capecitabine-treated O
group O
. O

Monitor O
platelet O
counts O
prior O
to O
initiation O
of O
KADCYLA O
and O
prior O
to O
each O
KADCYLA O
dose O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

KADCYLA O
has O
not O
been O
studied O
in O
patients O
with O
platelet B-Not_AE_Candidate
counts I-Not_AE_Candidate
< I-Not_AE_Candidate
1 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
, I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
/mm O
3 O
prior O
to O
initiation O
of O
treatment O
. O

In O
the O
event O
of O
decreased B-NonOSE_AE
platelet I-NonOSE_AE
count I-NonOSE_AE
to O
Grade O
3 O
or O
greater O
( O
< O
50,000/mm O
3 O
) O
do O
not O
administer O
KADCYLA O
until O
platelet O
counts O
recover O
to O
Grade O
1 O
( O
> O
= O
75,000/mm O
3 O
) O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

Patients O
with O
thrombocytopenia B-Not_AE_Candidate
( O
< O
100,000/mm O
3 O
) O
and O
patients O
on O
anti-coagulant O
treatment O
should O
be O
closely O
monitored O
during O
treatment O
with O
KADCYLA O
. O

5.8 O
Neurotoxicity B-OSE_Labeled_AE
Peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
mainly O
as O
Grade O
1 O
and O
predominantly O
sensory O
, O
was O
reported O
in O
clinical O
trials O
of O
KADCYLA O
( O
14 O
of O
884 O
treated O
patients O
with O
> O
= O
Grade O
3 O
; O
196 O
of O
884 O
treated O
patients O
with O
any O
Grade O
) O
. O

In O
the O
randomized O
trial O
( O
Study O
1 O
) O
, O
the O
overall O
frequency O
of O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
was O
21.2 O
% O
in O
the O
KADCYLA-treated O
group O
and O
13.5 O
% O
in O
the O
lapatinib O
plus O
capecitabine-treated O
group O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

The O
incidence O
of O
> O
= O
Grade O
3 O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
was O
2.2 O
% O
in O
the O
KADCYLA-treated O
group O
and O
0.2 O
% O
in O
the O
lapatinib O
plus O
capecitabine-treated O
group O
. O

KADCYLA O
should O
be O
temporarily O
discontinued O
in O
patients O
experiencing O
Grade O
3 O
or O
4 O
peripheral B-NonOSE_AE
neuropathy I-NonOSE_AE
until O
resolution O
to O
< O
= O
Grade O
2 O
. O

Patients O
should O
be O
clinically O
monitored O
on O
an O
ongoing O
basis O
for O
signs O
or O
symptoms O
of O
neurotoxicity B-NonOSE_AE
[ O
see O
Nonclinical O
Toxicology O
( O
13.2 O
) O
] O
. O

5.9 O
HER2 O
Testing O
Detection O
of O
HER B-Not_AE_Candidate
2 I-Not_AE_Candidate
protein I-Not_AE_Candidate
overexpression I-Not_AE_Candidate
or I-Not_AE_Candidate
gene I-Not_AE_Candidate
amplification I-Not_AE_Candidate
is O
necessary O
for O
selection O
of O
patients O
appropriate O
for O
KADCYLA O
therapy O
because O
these O
are O
the O
only O
patients O
studied O
for O
whom O
benefit O
has O
been O
shown O
[ O
see O
Indications O
and O
Usage O
( O
1 O
) O
, O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

In O
the O
randomized O
study O
( O
Study O
1 O
) O
, O
patients O
with O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
were O
required O
to O
have O
evidence O
of O
HER B-Not_AE_Candidate
2 I-Not_AE_Candidate
overexpression I-Not_AE_Candidate
defined O
as O
3+ O
IHC O
by O
Dako O
HerceptestTM O
or O
evidence O
of O
overexpression O
defined O
as O
FISH O
amplification O
ratio O
> O
= O
2.0 O
by O
Dako O
HER2 O
FISH O
PharmDxTM O
test O
kit O
. O

Only O
limited O
data O
were O
available O
for O
patients O
whose O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
was O
positive O
by O
FISH O
and O
0 O
or O
1+ O
by O
IHC O
. O

Assessment O
of O
HER2 O
status O
should O
be O
performed O
by O
laboratories O
with O
demonstrated O
proficiency O
in O
the O
specific O
technology O
being O
utilized O
. O

Improper O
assay O
performance O
, O
including O
use O
of O
sub- O
optimally O
fixed O
tissue O
, O
failure O
to O
utilize O
specified O
reagents O
, O
deviation O
from O
specific O
assay O
instructions O
, O
and O
failure O
to O
include O
appropriate O
controls O
for O
assay O
validation O
, O
can O
lead O
to O
unreliable O
results O
. O

5.10 O
Extravasation O
In O
KADCYLA O
clinical O
studies O
, O
reactions O
secondary O
to O
extravasation B-OSE_Labeled_AE
have O
been O
observed O
. O

These O
reactions O
, O
observed O
more O
frequently O
within O
24 O
hours O
of O
infusion O
, O
were O
usually O
mild O
and O
comprised O
erythema B-OSE_Labeled_AE
, O
tenderness O
, O
skin O
irrit O
at I-OSE_Labeled_AE
ion O
, O
pain O
, O
or O
swelling O
at O
the I-OSE_Labeled_AE
infusion I-OSE_Labeled_AE
site I-OSE_Labeled_AE
. O

Specific O
treatment O
for O
KADCYLA O
extravasation B-NonOSE_AE
is O
unknown O
. O

The O
infusion B-NonOSE_AE
site I-NonOSE_AE
should I-NonOSE_AE
be I-NonOSE_AE
closely I-NonOSE_AE
monitored I-NonOSE_AE
for I-NonOSE_AE
possible I-NonOSE_AE
subcutaneous I-NonOSE_AE
infiltration I-NonOSE_AE
during I-NonOSE_AE
drug I-NonOSE_AE
administration I-NonOSE_AE
. O

